多不饱和脂肪酸诱导的代谢耗竭与铁死亡损害MASLD中MAIT细胞的抗肿瘤功能
该研究在MASLD患者及共培养模型中直接离体检测MAIT细胞功能、代谢和抗癌活性,并用单细胞RNA测序将发现转化至MASLD及MASLD相关HCC临床队列。研究发现MASLD相关多不饱和脂肪酸(PUFAs)选择性蓄积于MAIT细胞而非传统CD8+ T细胞或NK细胞,通过细胞内脂质过氧化物形成驱动代谢耗竭和铁死亡,损害MAIT细胞效应功能与抗癌活性;干扰PUFA诱导的脂质过氧化物形成可逆转上述缺陷。HCC患者中与MAIT细胞功能障碍相关的MAIT细胞-PUFA基因特征高表达与较差生存相关。
要点
- MASLD患者MAIT细胞丧失效应功能,该缺陷由MASLD相关PUFAs选择性蓄积于MAIT细胞驱动。
- PUFAs通过脂质过氧化物形成导致MAIT细胞线粒体呼吸和糖酵解受损的代谢耗竭并引发铁死亡。
- 干扰PUFA诱导的脂质过氧化物形成可逆转代谢耗竭、防止铁死亡并恢复MAIT细胞抗癌活性。
核心结论
- 研究识别出一条新的免疫代谢轴,PUFAs在MASLD肝组织中蓄积,通过脂质过氧化物诱导的代谢耗竭和铁死亡驱动MAIT细胞功能障碍,最终损害其抗肿瘤活性。
- 该轴可能成为增强免疫治疗效果的靶向通路;靶向PUFA-脂质过氧化物轴可能恢复MAIT细胞功能并增强现有免疫治疗抗癌策略。
研究设计与样本
- 研究在MASLD患者中直接离体检测MAIT细胞功能、代谢和抗癌活性,并在模拟MASLD的共培养模型中研究。
- 使用(单细胞)RNA测序将发现转化至MASLD及MASLD相关HCC患者临床队列。
主要发现
- MASLD患者MAIT细胞丧失效应功能,MASLD相关PUFAs选择性蓄积于MAIT细胞,而不蓄积于传统CD8+ T细胞或NK细胞。
- PUFAs通过细胞内脂质过氧化物形成驱动MAIT细胞功能障碍,表现为线粒体呼吸和糖酵解受损的代谢耗竭状态。
- 该MASLD-PUFA-脂质过氧化物轴过度信号导致MAIT细胞铁死亡。
- 干扰PUFA诱导的MAIT细胞脂质过氧化物形成可逆转代谢耗竭、防止铁死亡,从而恢复MAIT细胞效应功能和抗癌活性。
- HCC患者中与MAIT细胞功能障碍相关的MAIT细胞-PUFA基因特征高表达与较差生存相关。
关键数值与推荐
- 原文未报告具体数值、阈值或推荐等级。
临床怎么用
- 作者认为靶向多不饱和脂肪酸-脂质过氧化物轴可能恢复MAIT细胞功能并增强现有免疫治疗抗癌策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Mucosal-associated invariant T (MAIT) cells constitute a highly abundant innate-like T-cell population in the human liver that is critical for immune surveillance of hepatic cancers. However, MAIT cells are often dysfunctional in human hepatocellular carcinoma (HCC), for reasons that remain unclear. Here, we aimed to identify the mechanisms driving MAIT cell dysfunction in metabolic dysfunction-associated steatotic liver disease (MASLD), a chronic liver condition that predisposes patients to HCC. METHODS: We studied MAIT cell functionality, metabolism and anti-cancer activity directly ex vivo in patients with MASLD, as well as in co-culture models mimicking MASLD. (Single-cell) RNA-sequencing was used to translate findings into clinical cohorts of patients with MASLD and MASLD-associated HCC. RESULTS: We found that MAIT cells lose their effector functions in patients with MASLD and uncover that this dysfunction is driven by MASLD-associated polyunsaturated fatty acids (PUFAs), which selectively accumulate in MAIT cells but not in conventional CD8+ T cells or NK cells. Mechanistically, PUFAs drive MAIT cell dysfunction through intracellular formation of lipid peroxides that promote a state of 'metabolic exhaustion' characterised by compromised mitochondrial respiration and glycolysis in MAIT cells. Excessive signalling through this MASLD-PUFA-lipid peroxide axis results in MAIT cell death by ferroptosis. Interference with PUFA-induced lipid peroxide formation in MAIT cells reversed their metabolic exhaustion and prevented ferroptotic MAIT cell death, thereby restoring MAIT cell effector function and anti-cancer activity. In patients with HCC, high expression of the MAIT cell-PUFA gene signature that was linked to MAIT cell dysfunction was associated with poor survival. CONCLUSIONS: Our findings identify a novel immunometabolic axis that impairs MAIT cell-mediated anti-cancer immunity in MASLD and may represent a targetable pathway to enhance the effectiveness of immunotherapy. IMPACT AND IMPLICATIONS: In this study, we identify a novel immunometabolic axis in which polyunsaturated fatty acids, accumulating in liver tissue in MASLD (metabolic dysfunction-associated steatotic liver disease), drive MAIT (mucosal-associated invariant T) cell dysfunction through lipid peroxide-induced metabolic exhaustion and ferroptosis, ultimately impairing their anti-tumour activity. These findings reveal how MASLD creates an immune-permissive environment that may facilitate hepatocellular carcinoma development and progression and prevent effective immunotherapy. Targeting the polyunsaturated fatty acid-lipid peroxide axis could restore MAIT cell function and enhance current immunotherapeutic anti-cancer strategies.
引用
- Deschler S, Pohl-Topcu J, Ramsauer L, et al. Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD. J Hepatol. 2025. PMID: 40543602. doi:10.1016/j.jhep.2025.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。